LivaNova (LIVN) stock has drawn attention after recent performance data showed a 15% move over the past month and a 67.7% total return over the past year, prompting closer scrutiny from investors.

The recent 15% 1 month share price return, alongside a 21.8% year to date share price gain and a 67.7% 1 year total shareholder return, points to momentum building around LivaNova as investors reassess its growth prospects and risks.

If this kind of move has you looking for what else is working in healthcare technology, it could be worth scanning a curated list of specialist opportunities through 34 healthcare AI stocks

With LivaNova trading at $73.83 and a value score of 2 alongside an indicated intrinsic discount of 16.6%, investors have to ask whether there is still a buying opportunity here or whether the market is already pricing in future growth.

Most Popular Narrative: 6.8% Undervalued

Based on the most followed narrative, LivaNova's fair value of $79.18 sits above the last close at $73.83, which puts the current run in a different light.

The company's clinical innovations, including strong, durable VNS study data in epilepsy and depression, launch of disruptive next-generation OSA neurostimulation (p-HGNS), and continued product upgrades (such as the Essenz platform's software upgradability), position LivaNova to capture share from the long-term shift toward minimally invasive, personalized therapies, which can drive pricing power and higher net margins.

Curious what kind of revenue path and margin profile are baked into that fair value, and how far earnings would need to stretch to support it.

The narrative applies an 8.6% discount rate and links the valuation to expectations around earnings growth, profitability and long term cash generation rather than short term share price moves. It effectively treats $79.18 as the anchor outcome if those assumptions on revenue, margins and future earnings multiples play out as outlined.

Result: Fair Value of $79.18 (UNDERVALUED)

However, the story can change quickly if reimbursement becomes less favorable or if competing treatments put pressure on procedure volumes in cardiopulmonary and neuromodulation.

Next Steps

With sentiment leaning positive, this is a good moment to look through the numbers yourself and pressure test the assumptions behind the story. To see what investors are optimistic about, take a closer look at the 3 key rewards

Looking for more investment ideas?

If LivaNova has sharpened your interest, do not stop here. Your next smart move could be spotting other stocks that match your goals using targeted screeners.

• Spot potential mispricings early by scanning a focused set of quality opportunities using the 48 high quality undervalued stocks.
• Prioritize resilience by zeroing in on companies that pass strict balance sheet checks through the solid balance sheet and fundamentals stocks screener (46 results).
• Stay one step ahead by checking a carefully filtered list of underfollowed opportunities via the screener containing 21 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.